Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen.

Infectious diseases remain an urgent and persistent global health threat, in both the developed and the developing world. Vaccines are recognized as the most cost-effective and successful approach to managing such diseases, yet traditional methods for discovering and developing vaccines are too slow and insufficiently comprehensive to meaningfully address the complexity of many pathogens.